AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

📰 Latest breakthroughs
🗺️ Disease Atlas · Reproductive system or breast disease

prostate cancer

A primary or metastatic malignant tumor involving the prostate gland. The vast majority are carcinomas.

🔔 Follow weekly
🧬10955genes / proteins with evidence
💊757drugs and clinical candidates
🧪12+recruiting trials worldwide
✅33approved
📈104phase 3
🧬

Understand prostate cancer

Cancer · Cells that grow out of control
🎓 Learn more

What it is

Cancer is a disease in which cells in the body grow out of control. Prostate cancer begins in the cells of the prostate. The prostate is a gland in the male reproductive system. It lies just below the bladder. It makes fluid that is part of semen.

Prostate cancer is one of the most common types of cancer. It often grows very slowly. If it does not spread to other parts of the body, it may not cause serious problems. But sometimes prostate cancer can grow quickly and spread to other parts of the body. This kind of prostate cancer is serious.

What causes prostate cancer?

From MedlinePlus: Prostate Cancer (US National Library of Medicine) ↗

🧬 Cancer: Cancer is a group of diseases in which some of the body's cells grow and divide without control, and can spread to other parts of the body.

❓ Why it happens

  • Changes (mutations) build up in the genes that tell a cell when to grow, divide and die.
  • Most of these changes happen during life: tobacco, too much sun, alcohol, some infections (such as HPV and hepatitis B and C), radiation, obesity and ageing all raise the risk.
  • Some people inherit a faulty gene that raises their risk, such as BRCA1 or BRCA2.

🫀 What it does to the body

  • Cancer cells form a lump (tumour) that can press on or invade nearby organs.
  • They can travel through the blood or lymph to start new tumours elsewhere (metastasis).
  • Blood cancers crowd out healthy blood cells in the bone marrow.

🧱 Why it is hard to cure

  • Every cancer is different, even between two people with the same type - and inside one tumour.
  • Cancer cells keep changing, so they can learn to resist a medicine that worked at first.
  • Cancer cells are the body's own cells, so killing them without harming healthy cells is hard.
  • Many cancers cause no symptoms until they have spread, and a new medicine often takes more than ten years to go from the lab to patients.

🚀 What research is trying now

  • Targeted medicines against the exact gene change in a tumour (for example EGFR, ALK or KRAS).
  • Immunotherapy that helps the immune system recognise cancer, including CAR-T cell therapy.
  • Personalised cancer vaccines built from each tumour's mutations, now in late trials.
  • Blood tests that look for tumour DNA to find cancer earlier, and AI to read scans and slides.

General information about cancer, reviewed by people; it does not describe any one person. Below: the evidence for prostate cancer itself.

🤖

AI briefing

Where the science on prostate cancer stands, from the evidence on this page

AI reads the targets, drugs, trials and papers below and writes where the science stands — every claim cited. It is shared with everyone who opens prostate cancer.

🎯

Top targets

Genes and proteins ranked by Open Targets evidence (0-1)
AR androgen receptorPROTACantibodysmall molecule🧊 AlphaFold structure ↗ 0.87
BRCA2 BRCA2 DNA repair associatedPROTACsmall molecule🧊 AlphaFold structure ↗ 0.85
PTEN phosphatase and tensin homologPROTACantibodysmall molecule🧊 AlphaFold structure ↗ 0.84
CHEK2 checkpoint kinase 2PROTACsmall molecule🧊 AlphaFold structure ↗ 0.80
TP53 tumor protein p53PROTACothersmall molecule🧊 AlphaFold structure ↗ 0.77
ATM ATM serine/threonine kinasePROTACsmall molecule🧊 AlphaFold structure ↗ 0.77
TMPRSS2 transmembrane serine protease 2PROTACantibodysmall molecule🧊 AlphaFold structure ↗ 0.74
ELAC2 elaC ribonuclease Z 2PROTACsmall molecule🧊 AlphaFold structure ↗ 0.74
HOXB13 homeobox B13PROTAC🧊 AlphaFold structure ↗ 0.74
FOXA1 forkhead box A1🧊 AlphaFold structure ↗ 0.73
SPOP speckle type BTB/POZ proteinPROTAC🧊 AlphaFold structure ↗ 0.72
KLK3 kallikrein related peptidase 3PROTACantibodysmall molecule🧊 AlphaFold structure ↗ 0.68
CDH1 cadherin 1PROTACantibodysmall molecule🧊 AlphaFold structure ↗ 0.67
CDK12 cyclin dependent kinase 12PROTACsmall molecule🧊 AlphaFold structure ↗ 0.67
ZFHX3 zinc finger homeobox 3PROTAC🧊 AlphaFold structure ↗ 0.67

Green labels: what the target is known to be druggable by. The score combines genetics, somatic mutations, drugs, expression and literature.

💊

Drugs and candidates

Every medicine linked to prostate cancer, by how far it has got
Approved · 20
AbarelixGonadotropin-releasing hormone receptor antagonistApproved
AbirateroneCytochrome P450 17A1 inhibitor; Androgen Receptor antagonistApproved
Abiraterone AcetateCytochrome P450 17A1 inhibitorApproved
ApalutamideAndrogen Receptor antagonistApproved
AtrasentanEndothelin receptor ET-A antagonistApproved
BicalutamideAndrogen Receptor antagonistApproved
Show all 20
CabazitaxelTubulin inhibitorApproved
CapromabProstate specific antigen binding agentApproved
Choline C-11Approved
CyproteroneApproved
DarolutamideAndrogen Receptor antagonistApproved
DegarelixGonadotropin-releasing hormone receptor antagonistApproved
Degarelix AcetateGonadotropin-releasing hormone receptor antagonistApproved
EnzalutamideAndrogen Receptor antagonistApproved
EstramustineApproved
Fluciclovine F18Approved
FlutamideAndrogen Receptor antagonistApproved
Histrelin AcetateGonadotropin-releasing hormone receptor agonistApproved
HydroxyflutamideApproved
LeuprolideGonadotropin-releasing hormone receptor agonistApproved
In phase 2 / 3 · 20
AbemaciclibCyclin-dependent kinase 4 inhibitor; Cyclin-dependent kinase 6 inhibitorPhase 3
AcetaminophenCyclooxygenase inhibitor; Anandamide amidohydrolase inhibitorPhase 3
AfliberceptVascular endothelial growth factor A inhibitor; Placenta growth factor inhibitorPhase 3
Aglatimagene BesadenovecPhase 3
AmonafidePhase 3
AspirinCyclooxygenase inhibitorPhase 3
Show all 20
AtezolizumabProgrammed cell death 1 ligand 1 inhibitorPhase 3
AtorvastatinHMG-CoA reductase inhibitorPhase 3
BevacizumabVascular endothelial growth factor A inhibitorPhase 3
BupivacaineSodium channel protein type IV alpha subunit blockerPhase 3
BuserelinGonadotropin-releasing hormone receptor agonistPhase 3
CabozantinibVascular endothelial growth factor receptor 2 inhibitor; Hepatocyte growth factor recepto…Phase 3
CalcitriolVitamin D receptor agonistPhase 3
CapivasertibSerine/threonine-protein kinase AKT inhibitorPhase 3
CarboplatinPhase 3
CholecalciferolVitamin D receptor agonistPhase 3
Clodronic AcidPhase 3
CustirsenClusterin mRNA antisense inhibitorPhase 3
Cyproterone AcetateAndrogen Receptor antagonist; Glucocorticoid receptor antagonistPhase 3
Dalteparin SodiumAntithrombin-III activatorPhase 3
Early trials · 20
2-Deoxy-D-GlucosePhase 1/2
Abt-751Tubulin beta inhibitorPhase 1/2
AcapatamabPhase 1/2
AdakitugInterleukin-8 inhibitorPhase 1/2
AfuresertibSerine/threonine-protein kinase AKT inhibitorPhase 1/2
AlobresibPhase 1/2
Show all 20
Amg-404Phase 1/2
Amonafide L-MalatePhase 1/2
Apc-100Androgen Receptor antagonistPhase 1/2
ApitolisibSerine/threonine-protein kinase mTOR inhibitor; PI3-kinase class I inhibitorPhase 1/2
Asp-9521Phase 1/2
Azd-9574Phase 1/2
BalstilimabProgrammed cell death protein 1 antagonistPhase 1/2
BavdegalutamidePhase 1/2
BavituximabPhase 1/2
BempegaldesleukinPhase 1/2
Bms-777607Hepatocyte growth factor receptor inhibitorPhase 1/2
CamptothecinPhase 1/2
CedazuridineCytidine deaminase inhibitorPhase 1/2
Cfg-920Phase 1/2
🧪

Recruiting trials

Worldwide, open to new patients now
ABlative Radiotherapy (for) Unfavorable Prostate TumorsNCT04831983 · n/a · 📍 MonzaProstate Tissue BioBankNCT06659614 · n/a · 📍 PhiladelphiaCombination Study of Antibiotics With Enzalutamide (PROMIZE)NCT06126731 · Phase 1, Phase 2 · 📍 BellinzonaValidation of a Platelet Proteomic Assay for Diagnosing and Monitoring Prostate CancerNCT07144228 · n/a · 📍 DurhamAdaptive Stereotactic Radiotherapy for Localized Prostate CancerNCT07344844 · NA · 📍 Saint-DenisArtificial Intelligence-based Platform, Integrating Pathologic, Imaging and Molecular Profiles of Prostate Ca…NCT06468332 · n/a · 📍 NovaraStudy to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid TumorsNCT04557449 · Phase 1, Phase 2 · 📍 Los AngelesLarge Language Model-Assisted cTNM Annotation From Chinese PSMA PET/CT ReportsNCT07707232 · n/a · 📍 WenzhouStudy of STM-416p Administered to Patients Undergoing Radical ProstatectomyNCT06450106 · Phase 1 · 📍 TucsonImperial Prostate 7 - Prostate Assessment Using Comparative Interventions - Fast Mri and Image-fusion for Can…NCT05574647 · NA · 📍 Southend-on-SeaSafety and Early Efficacy of Radical Prostatectomy for Newly Diagnosed Very High Risk Locally Advanced and Ol…NCT02971358 · NA · 📍 ViennaPRO-BOOST-LC: Whole-Gland Boost Strategies Versus SBRT Monotherapy in PSMA-Staged Localized and Locally Advan…NCT07426055 · Phase 2, Phase 3 · 📍 Zamość Search more trials →
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy